Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $165.00 at Wedbush

Revolution Medicines (NASDAQ:RVMD) had its price target boosted by Wedbush to $165.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts have also issued reports about the company. UBS Group started coverage on Revolution Medicines in a research report on Friday, February 27th. They issued a “buy” rating for the company. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Finally, HC Wainwright reiterated a “buy” rating on shares of Revolution Medicines in a research report on Wednesday, April 22nd. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines has a consensus rating of “Buy” and an average price target of $103.88.

Revolution Medicines Price Performance

Shares of RVMD opened at $142.51 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. The stock has a 50 day simple moving average of $113.41 and a 200 day simple moving average of $94.43. Revolution Medicines has a 52-week low of $34.00 and a 52-week high of $155.70. The firm has a market capitalization of $30.30 billion, a PE ratio of -20.16 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter last year, the business posted ($1.13) earnings per share. Sell-side analysts predict that Revolution Medicines will post -7.42 EPS for the current fiscal year.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. The trade was a 2.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the sale, the insider owned 295,398 shares in the company, valued at $29,386,193.04. The trade was a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 184,592 shares of company stock worth $24,499,532. Corporate insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after buying an additional 1,056,792 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Revolution Medicines by 194.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock valued at $1,696,000 after buying an additional 14,062 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Revolution Medicines by 39.3% in the 3rd quarter. New York State Common Retirement Fund now owns 119,807 shares of the company’s stock valued at $5,595,000 after buying an additional 33,821 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at approximately $921,000. Finally, Mass General Brigham Inc acquired a new stake in shares of Revolution Medicines in the 4th quarter valued at approximately $27,407,000. Institutional investors own 94.34% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: NEJM publication and pivotal trial momentum — Phase 1/2 daraxonrasib data were published and the company says those data support the RASolute 302 Phase 3 program; detailed results will be presented at ASCO and are planned for regulatory submissions, strengthening the approval pathway case. NEJM publication
• Positive Sentiment: Analyst upgrades/price-target lifts — multiple firms raised targets (Piper Sandler to $172, Wedbush and RBC to ~$165), signaling bullish analyst views on the commercial potential of RAS(ON) assets. Piper Sandler PT raise Other analyst notes
• Positive Sentiment: Balance-sheet strengthening — the company disclosed financings totaling roughly $2.2 billion in gross proceeds, reducing near-term cash risk and supporting late-stage development and potential commercial prep. Q1 results and financings
• Neutral Sentiment: Q1 earnings-call RAS program highlights — management emphasized RAS “wins” and program breadth on the call, which supports the long-term story but requires upcoming regulatory/readout milestones to translate into value. Earnings call highlights
• Negative Sentiment: Wider-than-expected Q1 loss and higher 2026 expense outlook — RVMD reported a larger net loss (EPS miss) and raised its 2026 expense guidance as R&D and commercial-prep costs climb, which pressures near-term profitability and drove part of the selloff. Zacks earnings coverage
• Negative Sentiment: Warrant expiry / dilution risk — commentary flagged warrants that expire in 2026, creating potential dilution if exercised (or worthlessness risk if not), a capital-structure risk investors are weighing. Warrants analysis

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.